title: Baseline Wall Thickness Is Lower in Mucosa-Healed Segments 1 Year After Infliximab in Pediatric Crohn Disease Patients.
abstract: We aimed to quantitatively investigate the therapeutic response to combined immunosuppression treatment by magnetic resonance enterography (MRE) in active luminal Crohn disease (CD) in the pediatric population.
  
  
  
  Pediatric patients with moderate-to-severe luminal CD, who received scheduled infliximab and azathioprine, were included in this preliminary study. Ileocolonoscopy and MRE were performed at baseline and at 1 year, and Simple Endoscopic Score for Crohn's Disease (SES-CD) and Magnetic Resonance Index of Activity (MaRIA) scores were calculated. The correlation between SES-CD and MaRIA scores were investigated with analysis per person and per segment.
  
  
  
  A total of 167 segments from 17 patients were evaluated by both Ileocolonoscopy and MRE. SES-CD and MaRIA scores showed significant correlations on both per-person analysis (ρ = 0.699, P < 0.001) and per-segment analysis (ρ = 0.596, P < 0.001). Analysis according to ileocolonic location of each segment revealed that the correlation strength was strongest in the right colon (ρ = 0.653, P < 0.001), whereas the correlation in the rectum was statistically insignificant (ρ = 0.29, P = 0.096). A comparative analysis of MaRIA components revealed a significantly thinner bowel wall thickness at baseline in endoscopically healed segments (50/65) compared with unhealed segments (15/65) (median 4.3 vs 7.2 mm, P = 0.036).
  
  
  
  Therapeutic response to combined immunosuppression at 1 year assessed by MRE correlates with ileocolonoscopy in pediatric patients with CD. Bowel wall thickness of the involved segments at baseline may affect treatment response to combined immunosuppression.
authors.affiliation: *Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine †Biostatistics and Clinical Epidemiology Center, Samsung Medical Center ‡Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Ben
authors.initials: B
authors.lastname: Kang
authors.forename: So Yoon
authors.initials: SY
authors.lastname: Choi
authors.forename: Sangah
authors.initials: S
authors.lastname: Chi
authors.forename: Yaeji
authors.initials: Y
authors.lastname: Lim
authors.forename: Tae Yeon
authors.initials: TY
authors.lastname: Jeon
authors.forename: Yon Ho
authors.initials: YH
authors.lastname: Choe
mesh_terms: D000293:Adolescent; D001379:Azathioprine / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D003106:Colon / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000473:pathology; D003113:Colonoscopy; D003424:Crohn Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007082:Ileum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000473:pathology; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000069285:Infliximab / Q000494:pharmacology / Q000627:therapeutic use*; D007413:Intestinal Mucosa / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000473:pathology; D016015:Logistic Models; D008279:Magnetic Resonance Imaging; D008297:Male; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000069285:Infliximab; D001379:Azathioprine